• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型蒽环类衍生物(SM - 5887)静脉注射给兔子后的心脏毒性:与阿霉素的对比研究

Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin.

作者信息

Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H

机构信息

Department of Laboratory Sciences, Gunma University School of Health Sciences, Japan.

出版信息

Invest New Drugs. 1997;15(3):219-25. doi: 10.1023/a:1005862730941.

DOI:10.1023/a:1005862730941
PMID:9387044
Abstract

The degree of cardiotoxicity of SM-5887 compared with that of doxorubicin was investigated in rabbits. Two experimental groups were administered high and low doses of SM-5887, respectively. One group was administered doxorubicin and another group was administered the vehicle only were prepared as positive and negative controls, respectively. Drugs were intravenously administered 3 times a week for 8 weeks. At terminus, electrocardiograms were recorded under anesthesia. The blood was collected for haematology and blood biochemistry analyses. Myocardial tissue damage was evaluated using light and electron microscopy. In the electrocardiogram study, prolongation of QTc interval and ST-T change were observed in rabbits administered SM-5887 and doxorubicin. Morphological studies showed that myocardial tissue damage in animals administered SM-5887 was comparable to that in the negative controls, and less than that observed in the positive controls. The general toxicological investigations uniformly indicated lower toxicity in the SM-5887 group than in the doxorubicin group at equivalent dosages. In total, considering the results of antitumor efficacy studies comparing SM-5887 with doxorubicin, these results indicate that the cardiotoxicity of SM-5887 is very slight, and that the general toxicity of SM-5887 is lower than that of doxorubicin.

摘要

在兔子身上研究了SM - 5887与阿霉素相比的心脏毒性程度。分别给两个实验组给予高剂量和低剂量的SM - 5887。一组给予阿霉素,另一组仅给予赋形剂,分别作为阳性和阴性对照。药物每周静脉注射3次,共8周。实验结束时,在麻醉状态下记录心电图。采集血液进行血液学和血液生化分析。使用光学显微镜和电子显微镜评估心肌组织损伤。在心电图研究中,给予SM - 5887和阿霉素的兔子出现QTc间期延长和ST - T改变。形态学研究表明,给予SM - 5887的动物心肌组织损伤与阴性对照相当,且小于阳性对照。一般毒理学研究一致表明,在等效剂量下,SM - 5887组的毒性低于阿霉素组。总体而言,考虑到比较SM - 5887与阿霉素的抗肿瘤疗效研究结果,这些结果表明SM - 5887的心脏毒性非常轻微,且SM - 5887的一般毒性低于阿霉素。

相似文献

1
Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin.新型蒽环类衍生物(SM - 5887)静脉注射给兔子后的心脏毒性:与阿霉素的对比研究
Invest New Drugs. 1997;15(3):219-25. doi: 10.1023/a:1005862730941.
2
Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits.柔红霉素和阿霉素对家兔慢性毒性作用的比较研究。
Hum Exp Toxicol. 2002 Dec;21(12):649-57. doi: 10.1191/0960327102ht311oa.
3
Heart fatty acid-binding protein may not be an early biomarker for anthracycline-induced cardiotoxicity in rabbits.心脏脂肪酸结合蛋白可能不是兔蒽环类药物诱导性心脏毒性的早期生物标志物。
Med Oncol. 2012 Sep;29(3):2303-8. doi: 10.1007/s12032-011-9843-x. Epub 2011 Feb 10.
4
Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.六种蒽环类药物对家兔的心脏毒性及比较药代动力学
Cancer Res. 1980 Oct;40(10):3530-6.
5
[A comparative study of 4'-epi-doxorubicin and doxorubicin cardiotoxicities].4'-表阿霉素与阿霉素心脏毒性的比较研究
Gan To Kagaku Ryoho. 1984 Oct;11(10):2170-6.
6
Toxicity of 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin and doxorubicin in nude mice bearing human tumour xenografts.3'-脱氨基-3'-(3-氰基-4-吗啉基)阿霉素和阿霉素对人肿瘤异种移植裸鼠的毒性
Anticancer Res. 1991 Sep-Oct;11(5):1855-62.
7
The rat model in the comparative evaluation of anthracyclines cardiotoxicity.用于蒽环类药物心脏毒性比较评估的大鼠模型。
Tumori. 1989 Dec 31;75(6):533-6. doi: 10.1177/030089168907500603.
8
Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.新型合成蒽环类衍生物(SM-5887)对比格犬正常心脏及阿霉素诱导的心肌病的慢性影响
Invest New Drugs. 1998;16(2):121-8. doi: 10.1023/a:1006088907271.
9
Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?释放一氧化氮的药物莫西多明的心脏保护作用是否可转化用于慢性蒽环类药物心脏毒性情况?
Toxicology. 2016 Nov 30;372:52-63. doi: 10.1016/j.tox.2016.11.002. Epub 2016 Nov 2.
10
Effect of octreotide in the prevention of doxorubicin cardiotoxicity.奥曲肽在预防阿霉素心脏毒性中的作用。
Anadolu Kardiyol Derg. 2005 Mar;5(1):18-23.

引用本文的文献

1
Novel Anthracycline Utorubicin for Cancer Therapy.用于癌症治疗的新型蒽环类药物乌托鲁比星
Angew Chem Weinheim Bergstr Ger. 2021 Jul 26;133(31):17155-17164. doi: 10.1002/ange.202016421. Epub 2021 Jun 1.
2
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor.单药氨柔比星治疗患者发热性中性粒细胞减少症的真实世界发病率:粒细胞集落刺激因子一级预防性给药的必要性
J Clin Med. 2021 Sep 17;10(18):4221. doi: 10.3390/jcm10184221.
3
Novel Anthracycline Utorubicin for Cancer Therapy.

本文引用的文献

1
The anthracycline antineoplastic drugs.蒽环类抗肿瘤药物。
N Engl J Med. 1981 Jul 16;305(3):139-53. doi: 10.1056/NEJM198107163050305.
2
[A comparative study of 4'-epi-doxorubicin and doxorubicin cardiotoxicities].4'-表阿霉素与阿霉素心脏毒性的比较研究
Gan To Kagaku Ryoho. 1984 Oct;11(10):2170-6.
3
Toxicological aspects of a novel 9-aminoanthracycline, SM-5887.新型9-氨基蒽环类药物SM-5887的毒理学研究
新型蒽环类药物乌托柔比星用于癌症治疗。
Angew Chem Int Ed Engl. 2021 Jul 26;60(31):17018-17027. doi: 10.1002/anie.202016421. Epub 2021 Jun 1.
4
Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.将 DNA 损伤与染色质损伤分离以解毒阿霉素。
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15182-15192. doi: 10.1073/pnas.1922072117. Epub 2020 Jun 17.
5
Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model.通过将多种分子效应整合到一个生物物理模型中来评估多柔比星心脏毒性的机制。
Br J Pharmacol. 2018 Mar;175(5):763-781. doi: 10.1111/bph.14104. Epub 2018 Jan 23.
6
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.氨柔比星/顺铂对比依托泊苷/顺铂作为广泛期小细胞肺癌一线治疗的随机III期试验
BMC Cancer. 2016 Apr 9;16:265. doi: 10.1186/s12885-016-2301-6.
7
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.合成型9-氨基蒽环类药物氨柔比星(SM-5887)作为转移性或不可切除软组织肉瘤患者一线治疗的II期研究:伴有TLS-CHOP易位的黏液样脂肪肉瘤的持久反应
Invest New Drugs. 2016 Apr;34(2):243-52. doi: 10.1007/s10637-016-0333-z. Epub 2016 Feb 20.
8
Recurrent pulmonary synovial sarcoma effectively treated with amrubicin: A case report.安柔比星有效治疗复发性肺滑膜肉瘤:一例报告
Exp Ther Med. 2015 May;9(5):1947-1949. doi: 10.3892/etm.2015.2308. Epub 2015 Feb 24.
9
The role of anthracyclines in small cell lung cancer.蒽环类药物在小细胞肺癌中的作用。
Ann Transl Med. 2013 Apr;1(1):5. doi: 10.3978/j.issn.2305-5839.2013.01.05.
10
Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride.盐酸氨柔比星治疗复发性小细胞肺癌的治疗进展。
Clin Med Insights Oncol. 2011 Mar 3;5:23-34. doi: 10.4137/CMO.S5072.
Jpn J Cancer Res. 1989 Jan;80(1):77-82. doi: 10.1111/j.1349-7006.1989.tb02248.x.
4
Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts.一种新型9-氨基蒽环类药物(SM-5887)对小鼠实验性肿瘤和人肿瘤异种移植瘤的抗肿瘤活性。
Jpn J Cancer Res. 1989 Jan;80(1):69-76. doi: 10.1111/j.1349-7006.1989.tb02247.x.
5
Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.阿霉素对小鼠心脏毒性的定量实验评估
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1877-83.
6
Cardiotoxicity of anthracycline antineoplastic drugs--Clinicopathological and experimental studies.蒽环类抗肿瘤药物的心脏毒性——临床病理与实验研究
Jpn Circ J. 1979 Nov;43(11):1000-8. doi: 10.1253/jcj.43.1000.
7
Overview of cardiac pathology in relation to anthracycline cardiotoxicity.与蒽环类药物心脏毒性相关的心脏病理学概述。
Cancer Treat Rep. 1978 Jun;62(6):955-61.